News provided by
Share this article
Share this article
Lead development candidate SG-5-00455 shows potential to become first in class PAI-1/2 inhibitor that directly targets mucosal healing in patients with inflammatory bowel disease (IBD)
BRISBANE, Calif., May 24, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, presented data demonstrating the Company's development candidate, SG-5-00455, improves epithelial barrier function and promotes mucosal healing by effectively inhibiting plasminogen activator inhibitor (PAI)-1/2 activity in the intestines. The data were presented at Digestive Disease Week 2022 Annual Meeting, held May 21-24 virtually and in San Diego, California. There is a strong correlation between the upregulation of SERPINE1 (PAI-1) and chronic inflammation in IBD. Local delivery of SG-5-00455 to the gastrointestinal mucosa of diseased mice demonstrated efficacy by inhibiting PAI-1 activity, which in excessive amounts adversely impacts wound healing, immune cell modulation and tissue remodeling. By selectively targeting the PAI-1 pathway at the mucosa, SG-5-00455 improves epithelial barrier function by regulating extracellular matrix production and reducing profibrotic inflammation. SG-5-00455 demonstrates the potential to directly target mucosal healing, a key therapeutic goal in the treatment of IBD," said Joseph Dal Proto, Ph.D. "SG-5-00455 has the potential to become a first-in-class treatment for patients with IBD in which mucosal healing is inadequately addressed by current standards of care." This data was presented during a poster session at DDW 2022. The information is provided below:
Session Title: Non-Immune Cells in Intestinal Inflammation: Epithelium and Stroma
Abstract Number: 3698252
Title: Identification and Development of a 1st in Class Naturally-Derived Protein that Drives Mucosal Healing and is Orally Delivered by an Engineered Cellular Therapy Targeting the Gastro-Intestinal Tract
In addition to SG-5-00455, Second Genome has presented data on the identification of immunomodulatory peptides with therapeutic potential using their proprietary technology-enabled platform (abstract number: 3699744) which was presented during another poster session at DDW 2022. SG-5-00455 is an orally delivered, engineered biotherapeutic modulator of the PAI1/2 pathway that is designed to work locally within the gastrointestinal tract to promote mucosal healing and improve barrier function in IBD patients. In vitro, SG-5-00455 demonstrated direct binding to PAI-1, functional inhibition of PAI-1/2 function and improvement in epithelial barrier function. In pre-clinical colitis models, oral administration of SG-5-00455 reduced pathology scores for inflammation and restored barrier function levels, as well as improved dysregulated tissue repair and fibrosis-associated gene expression and proteins levels. Mechanism of action studies revealed interaction with, and modulation of, fibrinolysis pathway members, which were found to be upregulated in IBD patient samples in multiple clinical cohorts. This will provide the basis for a potential biomarker to identify patients likely to respond to SG-5-00455. SG-5-00455 is currently in IND-enabling studies, and the Company anticipates filing an investigational new drug (IND) application with the U.S. FDA late 2022. The SG-5-00455 poster (#3698252) entitled, "Identification and Development of a 1st in Class Naturally-Derived Protein that Drives Mucosal Healing and is Orally Delivered by an Engineered Cellular Therapy Targeting the Gastro-Intestinal Tract," and the poster on the identification of immunomodulatory peptides utilizing our proprietary technology-enabled drug discovery platform (#3699744) will be made available on the Company's website at https://www.secondgenome.com/events/ . About Second Genome
Second Genome is a biotechnology company that leverages its proprietary technology-enabled platform to discover and develop transformational precision therapies based on novel microbial genetic insights. We built a proprietary drug discovery platform with machine-learning analytics, customized protein engineering techniques, phage library screening, mass spec analysis and gene-editing that we couple with traditional drug development approaches to progress the development of precision therapies for wide-ranging diseases. Second Genome is advancing lead programs in IBD and cancer into IND-enabling studies. We also collaborate with industry, academic and governmental partners to leverage our platform and data science capabilities. We hold a strategic collaboration with Gilead Sciences, Inc., utilizing our proprietary platform and comprehensive data sets to identify novel biomarkers associated with clinical response to Gilead's investigational medicines. We also hold a strategic collaboration with Pfizer (formerly Arena Pharmaceuticals) to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod. For more information, please visit www.secondgenome.com . Investor / Media Contact:

15:15 EDT
Second Genome Presents New Data at Digestive Disease Week (DDW) 2022 Demonstrating that SG-5-00455, a Potential First-...

News provided by
Share this article
Lead oncology program candidate SG-3-06686 shows potential to become first in class CXCR3 immune activator
BRISBANE, Calif., April 8, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, presented data demonstrating the Company's CXCR3 chemokine receptor modulator, SG-3-06686 (referred to as SG-3-00802DC in the AACR presentation), enhances effector T cell migration to improve the immune system's activity against tumors, and showed anti-tumor activity in preclinical models as a monotherapy and in combination with anti-Programmed Death Protein-1 (PD-1) treatment. The data is being presented at the American Association for Cancer Research (AACR) Annual Meeting, held April 8–13 virtually and in New Orleans, Louisiana. "We are excited about our pre-clinical data that show the ability of this potential mechanism to go beyond checkpoint blockade as an emerging new immunologic strategy for treating cancers. Checkpoint inhibitor therapy has been transformative for the clinical outcome of cancer patients and additional new checkpoint targets, such as TIGIT/LAG3, continue to be added to this important treatment approach. However, if the proper immune cells are underrepresented or lacking in the tumor microenvironment, these interventions tend to be less effective, and a significant portion of patients have limited or transient benefit. To augment and improve anti-tumor efficacy, we need to develop new therapeutics to better facilitate the ability of effector cells to access the tumor microenvironment. CXCR3 pathway modulation is a well validated and exciting approach to potentially enhance effector cell recruitment and improve existing immunotherapy interventions," said Joe Dal Porto, Ph.D., Chief Scientific Officer of Second Genome. "We look forward to submitting an investigational new drug (IND) application for SG-3-06686, a potential first in class CXCR3 immune modulator, in early 2023." This data presentation can be accessed during the online-only poster session at the AACR. The information is provided below:
Session Category: Clinical Research Excluding Trials
Session Title: Immuno-oncology
immune system to enhance anti-tumor immunity
SG-3-06686 is a potent CXCR3 chemokine receptor engager that acts as a positive allosteric modulator to increase receptor activity to the three known ligands (CXCL9/10/11). It has demonstrated to increase the activity of CXCL11 on CXCR3 activation by greater than 10-fold from a nM to a pM range with similar effects on CXCL9 and CXCL10. This activity in turn drives strong antitumor activity in several preclinical cancer models. The poster (#6349) entitled, "Targeting the CXCR3 pathway with a novel peptide drug candidate mobilizes the immune system to enhance anti-tumor immunity," will be available for on-demand viewing on the AACR website and will also be made available on the Company's website at https://www.secondgenome.com/events/ . About Second Genome
Second Genome is a biotechnology company that leverages its proprietary technology-enabled platform to discover and develop transformational precision therapies based on novel microbial genetic insights. We built a proprietary drug discovery platform with machine-learning analytics, customized protein engineering techniques, phage library screening, mass spec analysis and CRISPR, that we couple with traditional drug development approaches to progress the development of precision therapies for wide-ranging diseases. Second Genome is advancing lead programs in IBD and cancer into IND-enabling studies. We also collaborate with industry, academic and governmental partners to leverage our platform and data science capabilities. We hold a strategic collaboration with Gilead Sciences, Inc., utilizing our proprietary platform and comprehensive data sets to identify novel biomarkers associated with clinical response to Gilead's investigational medicines. We also hold a strategic collaboration with Pfizer (formerly Arena Pharmaceuticals) to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod. For more information, please visit www.secondgenome.com . Investor Contact:

13:00 EDT
Second Genome Presents New Preclinical Data at AACR 2022 Demonstrating that SG-3-06686, a CXCR3 Chemokine Receptor Mod...

Second Genome platform discovered diverse and novel proteins for Bayer for potential development of next-generation insect-control products
News provided by
Share this article
Share this article
BRISBANE, Calif., March 2, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced today it has completed its multi-year collaboration with Bayer to discover proteins for potential development of next-generation insect-control products. During the collaboration, Second Genome generated and explored environmental metagenomes that include genomic information from bacteria that are yet to be identified and cultured. "We are proud to have successfully executed a collaboration with Bayer following our discovery of thousands of novel proteins using our machine learning-enabled platform that have the potential to be developed into next-generation products," said Karim Dabbagh, Ph.D., President and Chief Executive Officer of Second Genome. "The discoveries Second Genome made are an important validation for the broad potential of our platform to develop novel therapeutic approaches for human health." Under the terms of this multi-year agreement, Second Genome generated a large microbial metagenomic dataset that was subsequently evaluated using a machine learning driven platform to identify novel insecticidal proteins. "With our vast human datasets, as well as our platform's machine learning, metagenomic and data standardization and analytic capabilities, we can efficiently analyze vast and geographically diverse data to advance Second Genome's pipeline of precision therapeutics and biomarkers and collaborators' portfolios," said Susannah Cantrell, Ph.D., Chief Operating Officer and Chief Business Officer of Second Genome. "We look forward to continuing to demonstrate the potential of our approach through additional industry collaborations in the health care field as we advance our lead mucosal healing and oncology programs toward the clinic this year." About Second Genome
Second Genome is a biotechnology company that leverages its proprietary technology-enabled platform to discover and develop transformational precision therapies based on novel microbial genetic insights. We built a proprietary drug discovery platform with machine-learning analytics, customized protein engineering techniques, phage library screening, mass spec analysis and CRISPR, that we couple with traditional drug development approaches to progress the development of precision therapies for wide-ranging diseases. Second Genome is advancing lead programs in IBD and cancer into IND-enabling studies. We also collaborate with industry, academic and governmental partners to leverage our platform and data science capabilities. We hold a strategic collaboration with Gilead Sciences, Inc., utilizing our proprietary platform and comprehensive data sets to identify novel biomarkers associated with clinical response to Gilead's investigational medicines. We also hold a strategic collaboration with Arena Pharmaceuticals to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod. For more information, please visit www.secondgenome.com . Investor Contact:

07:00 ET
Second Genome Announces Bayer Exercised Option Following Completion of Multi-Year Collaboration

SG-5-00455, the Company's development candidate for the treatment of IBD, aims to restore mucosal healing by targeting PAI-1/2
News provided by
Share this article
Share this article
BRISBANE, Calif., Feb. 24, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, yesterday hosted a virtual key opinion leader (KOL) event focused on the role of mucosal healing and plasminogen activator inhibitor (PAI)-1/2 in inflammatory bowel disease (IBD), and a briefing on SG-5-00455, the Company's development candidate for the treatment of IBD. "Following Second Genome's recent announcement on our nomination of SG-5-00455 to target PAI-1/2 for the treatment of IBD, we were pleased to host leading experts, Drs. Ryan Balfour Sartor and Silvio Danese, to discuss the importance of mucosal healing and targeting PAI 1/2," said Karim Dabbagh, Ph.D., President and Chief Executive Officer of Second Genome. "Their clinical perspectives on the need for novel, combination, personalized and targeted treatment approaches for IBD patients that aim to drive superior treatment outcomes through increased long-term mucosal healing reinforce the urgency with which we are working to advance SG-5-00455, now in investigational new drug (IND)-enabling studies." Addressing critical unmet needs in IBD through a novel approach that targets mucosal healing
The event included a presentation and a Q&A panel with renowned experts in the field, Ryan Balfour Sartor, M.D., Midgette Distinguished Professor of Medicine, Microbiology and Immunology and Co-Director of the University of North Carolina Multidisciplinary Center for IBD Research and Treatment, and Silvio Danese, M.D., Ph.D., Director, Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Professor of Gastroenterology at the University Vita-Salute San Raffaele in Milan, Italy. They underscored the importance of mucosal healing in IBD and some of the key factors that regulate gastrointestinal homeostasis. Remarked Dr. Balfour Sartor: "Clinically, I have several goals of therapy in IBD, including to induce sustained remission with mucosal healing, improve patients' quality of life and limit disease- and medication related complications. Mucosal healing is associated with better long-term clinical outcomes in ulcerative colitis and Crohn's disease and is now a U.S. Food and Drug Administration (FDA) metric for clinical trial outcomes. There are multiple strategies to target mucosal healing, and I believe this approach should improve the management of IBD patients." Commented Dr. Danese: "In our clinical practice, we see IBD as a very complex illness, and there is an opportunity to better align treatments with this reality. When we think about the future of treatment, it will be important to target the disease at the right stage, with the right drug, because the pathology is likely evolving throughout disease progression. Additionally, there is value in exploring a combination treatment approach to achieve a more profound control of inflammation." SG-5-00455's potential to become a first-in-class precision therapeutic directly targeting mucosal healing in IBD patients
This event follows the Company's presentation of new pre-clinical data during a digital oral presentation at the 17th Congress of European Crohn's and Colitis Organization (ECCO) held virtually February 16–19, 2022. Results demonstrated SG-5-00455 improves barrier function and promotes tissue repair through direct binding and modulation of PAI-1/2, and strong precision medicine potential to identify the target patient population using PAI-1/2 pathway biomarker(s). The presentation, "DOP54: Identification and development of a 1st in class naturally-derived protein that drives mucosal healing and is orally delivered by an engineered cellular therapy targeting the gastro-intestinal tract," can be found here , and the summary press release here . A replay of the presentation is accessible on the Events page of the Second Genome website at www.secondgenome.com/news/events . About SG-5-00455
SG-5-00455, the Company's development candidate targeting PAI-1/2 for the treatment of IBD, represents a potential first-in-class precision therapy for IBD by directly improving tissue repair and mucosal healing in IBD patients. The development candidate was generated using a novel, naturally derived protein (SG-2-0776), that was subsequently engineered into a Lactococcus lactis (L. lactis) drug delivery system, SG-5-00455, for direct, non-systemic delivery to the gut. SG-5-00455 is currently in IND-enabling studies, and the Company expects to submit an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) in the second half of 2022. About Second Genome
Second Genome is a biotechnology company that leverages its proprietary technology-enabled platform to discover and develop transformational precision therapies based on novel microbial genetic insights. We built a proprietary drug discovery platform with machine-learning analytics, customized protein engineering techniques, phage library screening, mass spec analysis and CRISPR, that we couple with traditional drug development approaches to progress the development of precision therapies for wide-ranging diseases. Second Genome is advancing lead programs in IBD and cancer into IND-enabling studies. We also collaborate with industry, academic and governmental partners to leverage our platform and data science capabilities. We hold a strategic collaboration with Gilead Sciences, Inc., utilizing our proprietary platform and comprehensive data sets to identify novel biomarkers associated with clinical response to Gilead's investigational medicines. We also hold a strategic collaboration with Arena Pharmaceuticals to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod. For more information, please visit www.secondgenome.com . Investor Contact:

07:00 ET
Second Genome Virtual KOL Event Highlighted Critical Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease ...

Company to unveil new preclinical data for SG-5-00455 at 17th Congress of European Crohn's and Colitis Organization (ECCO) plenary session on February 18, 2022
Virtual key opinion leader (KOL) event hosted by Company on role of mucosal healing andPAI-1/2 in IBD to occur on Wednesday, February 23 at 12 p.m. EST
News provided by
Share this article
Share this article
BRISBANE, Calif., Feb. 10, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, today announced that the Company will advance SG-5-00455, which targets plasminogen activator inhibitor (PAI)-1/2, as a development candidate for the treatment of inflammatory bowel disease (IBD). The Company will present new preclinical data on SG-5-00455 at the virtual 17th Congress of European Crohn's and Colitis Organization (ECCO) on February 18, 2022. "We are excited to be moving SG-5-00455, our development candidate for the treatment of IBD, one step closer to patients. With its PAI-1/2 inhibition mechanism of action, we are targeting a well validated pathway that has been shown to play an important role in the pathophysiology of IBD. We believe that direct modulation of tissue repair pathways has the potential to directly improve mucosal healing and drive superior therapeutic outcomes, including when combined with the current standard of care anti-inflammatory approaches," said Karim Dabbagh, Ph.D., President and Chief Executive Officer of Second Genome. "This is an important milestone for Second Genome's internal pipeline. We look forward to presenting new data at ECCO'22 and hosting our upcoming IBD KOL expert panel, both of which are occurring later this month, as we plan to file an investigational new drug (IND) application for SG-5-00455 in the second half of 2022." SG-5-00455 could potentially be a first-in-class precision therapeutic that directly targets mucosal healing in IBD patients. The development candidate was generated using a novel, naturally derived protein (SG-2-0776), that was subsequently engineered into an Lactococcus lactis (L. lactis) drug delivery system, SG-5-00455, for direct, non-systemic delivery to the gut. This enables precise targeting of mucosal healing, a key therapeutic goal for IBD and an important U.S. Food and Drug Administration (FDA) metric for clinical trial outcomes. At ECCO'22, Second Genome's Chief Science Officer, Joseph Dal Porto, Ph.D. will present, "DOP54: Identification and development of a 1st in class naturally-derived protein that drives mucosal healing and is orally delivered by an engineered cellular therapy targeting the gastro-intestinal tract," during the Virtual Plenary Hall session, "DOP Session 6: The Artic: IBD Basic Science," taking place on Friday, February 18, 2022, at 5:25 – 6:25 EST (17:25 – 18:25 CEST). On Wednesday, February 23, 2022, at 12:00 – 1:00 p.m. EST, Second Genome will host a virtual KOL panel, "SG-5-00455 and the Role of Mucosal Healing and PAI-1/2 in IBD." Additional details about the event will be announced publicly and a link to the event will be available on the Company's website at https://www.secondgenome.com . About Second Genome
Second Genome is a biotechnology company that leverages its proprietary technology-enabled platform to discover and develop transformational precision therapies based on novel microbial genetic insights. We built a proprietary drug discovery platform with machine-learning analytics, customized protein engineering techniques, phage library screening, mass spec analysis and CRISPR, that we couple with traditional drug development approaches to progress the development of precision therapies for wide-ranging diseases. Second Genome is advancing lead programs in IBD and cancer into IND-enabling studies. We also collaborate with industry, academic and governmental partners to leverage our platform and data science capabilities. We hold a strategic collaboration with Gilead Sciences, Inc., utilizing our proprietary platform and comprehensive data sets to identify novel biomarkers associated with clinical response to Gilead's investigational medicines. We also hold a strategic collaboration with Arena Pharmaceuticals to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod. For more information, please visit www.secondgenome.com . Investor Contact:

Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)

PRISA is a Spanish and Portuguese-language business group focused on the fields of education, information and entertainment. It has a presence in Brazil and Portugal as well as with the Hispanic community in the US.

PRISA

Assured Labor , Inc. launched its job platform , EmpleoListo , in Mexico in October 2010 in collaboration with the country s largest wireless carriers .

Assured Labor PRISA DIGITAL PARTNERS WITH ASSURED LABOR AS IT ADDS OVER 100,000 USERS IN MEXICO

Invested Development

Gradeable

Isovia

Innosight

CreditSights

Accenture

The Muse

Bevi

Monster Worldwide

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

 HR tech startups are helping companies manage critical pain points in HR processes such as recruitment, automation, career development, compensation, and benefits management, through a mix of software and services.

HR Tech

Bernardo  Paasche

Everardo  Camacho

Series A

Series B

Assured Labor revolutionizes hiring in emerging markets. The service leverages the power of mobile phones and the Internet to rapidly connect employers with the best mid-to-low wage candidates in their area. Assured Labor's disruptive platform is optimized for the realities of the Emerging Markets where 3 of 4 Internet users access the web sporadically and nearly everyone has a cell phone.

Name	Work History	Title	Status
Ximena Fernandez Ordonez		Founder	Former
Siddhartha Goyal	Invested Development, Gradeable, and Isovia	Founder, Chief Technology Officer	Former
David Reich	Innosight, CreditSights, and Accenture	Founder	Former
John Hyland	The Muse, Bevi, Monster Worldwide, and PTC	Chief Operating Officer	Former
Joseph Bamber		Chief Marketing Officer	Former

Name	Ximena Fernandez Ordonez	Siddhartha Goyal	David Reich	John Hyland	Joseph Bamber
Work History		Invested Development, Gradeable, and Isovia	Innosight, CreditSights, and Accenture	The Muse, Bevi, Monster Worldwide, and PTC
Title	Founder	Founder, Chief Technology Officer	Founder	Chief Operating Officer	Chief Marketing Officer
Status	Former	Former	Former	Former	Former

Wells Fargo Success Story

3M Success Story

Platform Overview

Assured Labor

Executives

Assured Labor Management Team

5 Team Members

Discover the right solution for your team